🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Rose Parisi

Memorial Sloan Kettering Cancer Center

ORCID: 0000-0003-2454-6895

Also affiliated with Brown University, Albany Medical Center Hospital

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “Dermatologic adverse events in acute lymphocytic leukemia patients treated with bispecific T-cell engager blinatumomab”.

Dermatologic adverse events in acute lymphocytic leukemia patients treated with bispecific T-cell engager blinatumomab

Leukemia & lymphoma/Leukemia and lymphoma(2023)10.1080/10428194.2023.2221756
N/A
0.269DataRank · unranked
5 citations

Emily A. Cowen, Stephanie Gu, Stephen W. Dusza, Melissa Pulitzer, Mark B. Geyer +3 more

Dermatologic Adverse Events Following CD19-Directed CAR T-Cell Therapy in Hematologic Malignancies

Clinical Lymphoma Myeloma & Leukemia(2025)10.1016/j.clml.2025.09.012
N/A
0.104DataRank · unranked
1 citations

Rachel Reingold, Rose Parisi, Stephen W. Dusza, Sarah Noor, Jae H. Park +9 more

Dermatologic adverse events associated with IDH inhibitors ivosidenib and enasidenib for the treatment of acute myeloid leukemia

Leukemia Research(2022)10.1016/j.leukres.2022.106970
N/A
0DataRank · unranked
8 citations

Emily A. Cowen, Joseph R. Stoll, Haoling Zhu, Stephen W. Dusza, Melissa Pulitzer +3 more

Update on Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Diagnosis and Management

American Journal of Clinical Dermatology(2024)10.1007/s40257-024-00889-6
N/A
0DataRank · unranked
88 citations

Rose Parisi, Eric Mukherjee, Elizabeth J. Phillips, Roni P. Dodiuk‐Gad, Hemali Shah

Mucocutaneous Adverse Events in Patients With Cancer Treated with the Highly Selective RET Kinase Inhibitor Selpercatinib (LOXO-292)

JTO Clinical and Research Reports(2025)10.1016/j.jtocrr.2025.100792
N/A
0DataRank · unranked
3 citations

Rose Parisi, Guilherme Harada, Andrea P. Moy, George Dranitsaris, Jasmine H. Francis +7 more